Thank you very much, Madam Chair.
Dr. Innes, you were talking about this way of looking at a broader...almost covering someone's DNA.
How far down is this in terms of research? How far has it gone, and what countries are using it, if at all? If you see it being used extensively, what cost savings do you see being achieved by doing that? That's the first question I wanted to ask.
The second one is, as you well know biologics are being used quite often to deal with some rare diseases. What do you see as the benefit of new drugs coming out that are, for want of a better word, generic versions of biologics that are coming out of certain developing countries? As we look at cheaper ways of dealing with rare diseases, what do you see as the downside to that? I wonder if you see this as a risk that might cause problems because, as you well know, generic drugs don't always have the same molecular structure or even efficacy as some of the pharma drugs.